郑刚, 张承宗. 临床试验对不同低分子肝素在急性冠状动脉综合征治疗效果的评价[J]. 循证医学, 2003, 3(1): 22-25. DOI: 10.3969/j.issn.1671-5144.2003.01.006
    引用本文: 郑刚, 张承宗. 临床试验对不同低分子肝素在急性冠状动脉综合征治疗效果的评价[J]. 循证医学, 2003, 3(1): 22-25. DOI: 10.3969/j.issn.1671-5144.2003.01.006
    The evaluation of clinical trials on different low molecular weight heparins in the efficacy of treatment in patients with acute coronary syndromes[J]. Journal of Evidence-Based Medicine, 2003, 3(1): 22-25. DOI: 10.3969/j.issn.1671-5144.2003.01.006
    Citation: The evaluation of clinical trials on different low molecular weight heparins in the efficacy of treatment in patients with acute coronary syndromes[J]. Journal of Evidence-Based Medicine, 2003, 3(1): 22-25. DOI: 10.3969/j.issn.1671-5144.2003.01.006

    临床试验对不同低分子肝素在急性冠状动脉综合征治疗效果的评价

    The evaluation of clinical trials on different low molecular weight heparins in the efficacy of treatment in patients with acute coronary syndromes

    • 摘要: 临床试验研究使我们明确认识到低分子肝素在治疗急性冠状动脉综合征中已具有取代普通肝素的地位,成为急性冠状动脉综合征患者急性期治疗的新标准.但是,不同种类低分子肝素是有独特的化学、药代动力学及药效学特点的合成物.每一种制剂都有不尽相同的抗凝特点,可以通过抗凝血酶(抗Xa:Ⅱa的比值)及凝血酶介导的作用反应出来.低分子肝素在治疗急性冠状动脉综合征临床试验中显示出不同结果,说明一种制剂的临床结果不能扩展到另一种制剂,治疗上不能互换.

       

    /

    返回文章
    返回